Two year survival for Concurrent Carboplatin, Paclitaxel, and Hyperfractionated Radiotherapy in Unresectable Head and Neck Cancer.

Reviewer: Tracy d'Entremont, MD
OncoLink
Ultima Vez Modificado: 31 de mayo del 2003

Translation for this article does not exist